BG103946A - Инхибитори на фарнезилтрансфераза в комбинация с инхибитори на нмg соа редуктаза за лечение на рак - Google Patents

Инхибитори на фарнезилтрансфераза в комбинация с инхибитори на нмg соа редуктаза за лечение на рак Download PDF

Info

Publication number: BG103946A
Authority: BG; Bulgaria
Prior art keywords: alkyl; phenyl; coa reductase; inhibitor; hmg coa
Prior art date: 1997-06-16

Application number

BG103946A

Other languages

Bulgarian (bg)

English (en)

Inventor

Shama Kajiji

Original Assignee

Pfizer Products Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-06-16

Filing date

1999-12-03

Publication date

2000-07-31

1999-12-03 Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.

2000-07-31 Publication of BG103946A publication Critical patent/BG103946A/bg

Links

206010028980 Neoplasm Diseases 0.000 title claims abstract description 25
201000011510 cancer Diseases 0.000 title claims abstract description 19
239000003112 inhibitor Substances 0.000 title claims description 47
102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 title description 9
108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 title description 9
229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims abstract description 29
239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims abstract description 29
241000124008 Mammalia Species 0.000 claims abstract description 16
-1 nitro, cyano, phenyl Chemical group 0.000 claims description 51
238000000034 method Methods 0.000 claims description 42
150000001875 compounds Chemical class 0.000 claims description 40
239000008194 pharmaceutical composition Substances 0.000 claims description 28
229910052739 hydrogen Inorganic materials 0.000 claims description 25
125000001424 substituent group Chemical group 0.000 claims description 24
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 22
125000000217 alkyl group Chemical group 0.000 claims description 21
125000005843 halogen group Chemical group 0.000 claims description 21
230000002159 abnormal effect Effects 0.000 claims description 20
239000001257 hydrogen Substances 0.000 claims description 17
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 16
230000011712 cell development Effects 0.000 claims description 15
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 15
239000000203 mixture Substances 0.000 claims description 14
210000004027 cell Anatomy 0.000 claims description 13
201000010099 disease Diseases 0.000 claims description 13
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 13
125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 12
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 12
230000002062 proliferating effect Effects 0.000 claims description 12
125000001153 fluoro group Chemical group F* 0.000 claims description 11
230000002401 inhibitory effect Effects 0.000 claims description 10
125000004093 cyano group Chemical group *C#N 0.000 claims description 9
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 8
PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 claims description 8
239000013543 active substance Substances 0.000 claims description 8
125000003118 aryl group Chemical group 0.000 claims description 8
239000003937 drug carrier Substances 0.000 claims description 8
150000002431 hydrogen Chemical class 0.000 claims description 8
230000005764 inhibitory process Effects 0.000 claims description 8
229960004844 lovastatin Drugs 0.000 claims description 8
PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 claims description 8
QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 claims description 8
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 8
150000003839 salts Chemical class 0.000 claims description 8
125000000623 heterocyclic group Chemical group 0.000 claims description 7
125000003670 adamantan-2-yl group Chemical group [H]C1([H])C(C2([H])[H])([H])C([H])([H])C3([H])C([*])([H])C1([H])C([H])([H])C2([H])C3([H])[H] 0.000 claims description 6
229910052799 carbon Inorganic materials 0.000 claims description 6
238000011161 development Methods 0.000 claims description 6
230000018109 developmental process Effects 0.000 claims description 6
125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 5
XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 claims description 5
XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 claims description 5
239000004480 active ingredient Substances 0.000 claims description 5
229960005370 atorvastatin Drugs 0.000 claims description 5
125000001246 bromo group Chemical group Br* 0.000 claims description 5
125000001309 chloro group Chemical group Cl* 0.000 claims description 5
125000002346 iodo group Chemical group I* 0.000 claims description 5
125000006559 (C1-C3) alkylamino group Chemical group 0.000 claims description 4
125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims description 4
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 4
TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 claims description 4
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 4
125000002947 alkylene group Chemical group 0.000 claims description 4
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 4
125000000753 cycloalkyl group Chemical group 0.000 claims description 4
125000001624 naphthyl group Chemical group 0.000 claims description 4
229910052760 oxygen Inorganic materials 0.000 claims description 4
239000001301 oxygen Substances 0.000 claims description 4
229960002965 pravastatin Drugs 0.000 claims description 4
TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 claims description 4
125000003373 pyrazinyl group Chemical group 0.000 claims description 4
125000003226 pyrazolyl group Chemical group 0.000 claims description 4
125000000714 pyrimidinyl group Chemical group 0.000 claims description 4
229910052717 sulfur Inorganic materials 0.000 claims description 4
239000011593 sulfur Substances 0.000 claims description 4
125000001425 triazolyl group Chemical group 0.000 claims description 4
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 4
ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 claims description 3
125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims description 3
125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims description 3
RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 claims description 3
125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 claims description 3
125000003545 alkoxy group Chemical group 0.000 claims description 3
229960003765 fluvastatin Drugs 0.000 claims description 3
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
229920006395 saturated elastomer Polymers 0.000 claims description 3
229960002855 simvastatin Drugs 0.000 claims description 3
RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 claims description 3
125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 2
KPPVNWGJXFMGAM-UUILKARUSA-N (e)-2-methyl-1-(6-methyl-3,4-dihydro-2h-quinolin-1-yl)but-2-en-1-one Chemical compound CC1=CC=C2N(C(=O)C(/C)=C/C)CCCC2=C1 KPPVNWGJXFMGAM-UUILKARUSA-N 0.000 claims description 2
125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 2
125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 claims description 2
125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 2
125000004070 6 membered heterocyclic group Chemical group 0.000 claims description 2
125000002541 furyl group Chemical group 0.000 claims description 2
125000000842 isoxazolyl group Chemical group 0.000 claims description 2
125000004433 nitrogen atom Chemical group N* 0.000 claims description 2
125000002971 oxazolyl group Chemical group 0.000 claims description 2
125000003718 tetrahydrofuranyl group Chemical group 0.000 claims description 2
125000003831 tetrazolyl group Chemical group 0.000 claims description 2
125000000335 thiazolyl group Chemical group 0.000 claims description 2
125000001544 thienyl group Chemical group 0.000 claims description 2
125000000008 (C1-C10) alkyl group Chemical group 0.000 claims 2
125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 1
210000004962 mammalian cell Anatomy 0.000 claims 1
230000000694 effects Effects 0.000 description 12
108010014186 ras Proteins Proteins 0.000 description 11
239000003814 drug Substances 0.000 description 10
102000016914 ras Proteins Human genes 0.000 description 10
JFDZBHWFFUWGJE-UHFFFAOYSA-N benzenecarbonitrile Natural products N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 9
101710113436 GTPase KRas Proteins 0.000 description 8
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
102000004190 Enzymes Human genes 0.000 description 6
108090000790 Enzymes Proteins 0.000 description 6
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
229940088598 enzyme Drugs 0.000 description 6
238000002360 preparation method Methods 0.000 description 6
229940124597 therapeutic agent Drugs 0.000 description 6
241000282412 Homo Species 0.000 description 5
241000700159 Rattus Species 0.000 description 5
VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 5
108090000623 proteins and genes Proteins 0.000 description 5
NPOAOTPXWNWTSH-UHFFFAOYSA-N 3-hydroxy-3-methylglutaric acid Chemical compound OC(=O)CC(O)(C)CC(O)=O NPOAOTPXWNWTSH-UHFFFAOYSA-N 0.000 description 4
108700020796 Oncogene Proteins 0.000 description 4
108010029485 Protein Isoforms Proteins 0.000 description 4
102000001708 Protein Isoforms Human genes 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 4
108010050749 geranylgeranyltransferase type-I Proteins 0.000 description 4
238000010348 incorporation Methods 0.000 description 4
230000013823 prenylation Effects 0.000 description 4
239000000243 solution Substances 0.000 description 4
239000006228 supernatant Substances 0.000 description 4
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
108010007508 Farnesyltranstransferase Proteins 0.000 description 3
102000007317 Farnesyltranstransferase Human genes 0.000 description 3
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 3
230000004913 activation Effects 0.000 description 3
239000002246 antineoplastic agent Substances 0.000 description 3
229940125904 compound 1 Drugs 0.000 description 3
229940079593 drug Drugs 0.000 description 3
208000014829 head and neck neoplasm Diseases 0.000 description 3
208000020816 lung neoplasm Diseases 0.000 description 3
230000035772 mutation Effects 0.000 description 3
231100000590 oncogenic Toxicity 0.000 description 3
230000002246 oncogenic effect Effects 0.000 description 3
239000000126 substance Substances 0.000 description 3
238000003786 synthesis reaction Methods 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
210000004881 tumor cell Anatomy 0.000 description 3
XMGQYMWWDOXHJM-JTQLQIEISA-N (+)-α-limonene Chemical compound CC(=C)[C@@H]1CCC(C)=CC1 XMGQYMWWDOXHJM-JTQLQIEISA-N 0.000 description 2
KJTLQQUUPVSXIM-ZCFIWIBFSA-M (R)-mevalonate Chemical compound OCC[C@](O)(C)CC([O-])=O KJTLQQUUPVSXIM-ZCFIWIBFSA-M 0.000 description 2
KUSOTJDEOIJCRU-UHFFFAOYSA-N 4-[2-[5-oxo-4,4-bis(pyridin-4-ylmethyl)-1-[(4,6,6-trimethyl-3-bicyclo[3.1.1]heptanyl)methyl]imidazolidin-2-ylidene]acetyl]benzonitrile Chemical compound CC1C(C2(C)C)CC2CC1CN(C1=O)C(=CC(=O)C=2C=CC(=CC=2)C#N)NC1(CC=1C=CN=CC=1)CC1=CC=NC=C1 KUSOTJDEOIJCRU-UHFFFAOYSA-N 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
235000005979 Citrus limon Nutrition 0.000 description 2
244000131522 Citrus pyriformis Species 0.000 description 2
206010009944 Colon cancer Diseases 0.000 description 2
KJTLQQUUPVSXIM-UHFFFAOYSA-N DL-mevalonic acid Natural products OCCC(O)(C)CC(O)=O KJTLQQUUPVSXIM-UHFFFAOYSA-N 0.000 description 2
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
206010058467 Lung neoplasm malignant Diseases 0.000 description 2
102000043276 Oncogene Human genes 0.000 description 2
206010061902 Pancreatic neoplasm Diseases 0.000 description 2
206010039491 Sarcoma Diseases 0.000 description 2
PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
208000024770 Thyroid neoplasm Diseases 0.000 description 2
229920004890 Triton X-100 Polymers 0.000 description 2
239000013504 Triton X-100 Substances 0.000 description 2
230000001594 aberrant effect Effects 0.000 description 2
230000001093 anti-cancer Effects 0.000 description 2
230000000340 anti-metabolite Effects 0.000 description 2
239000002256 antimetabolite Substances 0.000 description 2
229940100197 antimetabolite Drugs 0.000 description 2
239000007900 aqueous suspension Substances 0.000 description 2
239000011324 bead Substances 0.000 description 2
230000037396 body weight Effects 0.000 description 2
230000023715 cellular developmental process Effects 0.000 description 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
210000001072 colon Anatomy 0.000 description 2
230000030944 contact inhibition Effects 0.000 description 2
230000001086 cytosolic effect Effects 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
208000035475 disorder Diseases 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
230000006126 farnesylation Effects 0.000 description 2
239000000945 filler Substances 0.000 description 2
230000014509 gene expression Effects 0.000 description 2
210000004185 liver Anatomy 0.000 description 2
201000005202 lung cancer Diseases 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
230000003211 malignant effect Effects 0.000 description 2
239000012528 membrane Substances 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
201000002528 pancreatic cancer Diseases 0.000 description 2
208000008443 pancreatic carcinoma Diseases 0.000 description 2
230000037361 pathway Effects 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
XOKSLPVRUOBDEW-UHFFFAOYSA-N pinane Chemical compound CC1CCC2C(C)(C)C1C2 XOKSLPVRUOBDEW-UHFFFAOYSA-N 0.000 description 2
125000001844 prenyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
235000018102 proteins Nutrition 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
108700042226 ras Genes Proteins 0.000 description 2
235000019333 sodium laurylsulphate Nutrition 0.000 description 2
239000007787 solid Substances 0.000 description 2
239000002904 solvent Substances 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
230000002195 synergetic effect Effects 0.000 description 2
239000003826 tablet Substances 0.000 description 2
150000003505 terpenes Chemical class 0.000 description 2
238000012360 testing method Methods 0.000 description 2
230000009466 transformation Effects 0.000 description 2
CABVTRNMFUVUDM-VRHQGPGLSA-N (3S)-3-hydroxy-3-methylglutaryl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C[C@@](O)(CC(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 CABVTRNMFUVUDM-VRHQGPGLSA-N 0.000 description 1
125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 1
VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 description 1
PXBCTWZAUYVFOE-UHFFFAOYSA-N 2-[2-(2,4-difluorophenyl)-2-oxoethylidene]-5,5-bis(pyridin-4-ylmethyl)-3-[(4,6,6-trimethyl-3-bicyclo[3.1.1]heptanyl)methyl]imidazolidin-4-one Chemical compound CC1C(C2(C)C)CC2CC1CN(C1=O)C(=CC(=O)C=2C(=CC(F)=CC=2)F)NC1(CC=1C=CN=CC=1)CC1=CC=NC=C1 PXBCTWZAUYVFOE-UHFFFAOYSA-N 0.000 description 1
DVPVDMLOUFFHME-UHFFFAOYSA-N 2-[2-(3,4-dichlorophenyl)-2-oxoethylidene]-5,5-bis(pyridin-4-ylmethyl)-3-[(4,6,6-trimethyl-3-bicyclo[3.1.1]heptanyl)methyl]imidazolidin-4-one Chemical compound CC1C(C2(C)C)CC2CC1CN(C1=O)C(=CC(=O)C=2C=C(Cl)C(Cl)=CC=2)NC1(CC=1C=CN=CC=1)CC1=CC=NC=C1 DVPVDMLOUFFHME-UHFFFAOYSA-N 0.000 description 1
QHCRCICUXFINMF-UHFFFAOYSA-N 2-[2-(4-methylsulfonylphenyl)-2-oxoethylidene]-5,5-bis(pyridin-4-ylmethyl)-3-[(4,6,6-trimethyl-3-bicyclo[3.1.1]heptanyl)methyl]imidazolidin-4-one Chemical compound CC1C(C2(C)C)CC2CC1CN(C1=O)C(=CC(=O)C=2C=CC(=CC=2)S(C)(=O)=O)NC1(CC=1C=CN=CC=1)CC1=CC=NC=C1 QHCRCICUXFINMF-UHFFFAOYSA-N 0.000 description 1
WFTMWGACLUBALJ-UHFFFAOYSA-N 2-[2-(4-nitrophenyl)-2-oxoethylidene]-5,5-bis(pyridin-4-ylmethyl)-3-[(4,6,6-trimethyl-3-bicyclo[3.1.1]heptanyl)methyl]imidazolidin-4-one Chemical compound CC1C(C2(C)C)CC2CC1CN(C1=O)C(=CC(=O)C=2C=CC(=CC=2)[N+]([O-])=O)NC1(CC=1C=CN=CC=1)CC1=CC=NC=C1 WFTMWGACLUBALJ-UHFFFAOYSA-N 0.000 description 1
YMGOKNBGZSEVQB-UHFFFAOYSA-N 2-[2-oxo-2-(4-phenylphenyl)ethylidene]-5,5-bis(pyridin-4-ylmethyl)-3-[(4,6,6-trimethyl-3-bicyclo[3.1.1]heptanyl)methyl]imidazolidin-4-one Chemical compound CC1C(C2(C)C)CC2CC1CN(C1=O)C(=CC(=O)C=2C=CC(=CC=2)C=2C=CC=CC=2)NC1(CC=1C=CN=CC=1)CC1=CC=NC=C1 YMGOKNBGZSEVQB-UHFFFAOYSA-N 0.000 description 1
CQPLXXQRHANTEN-UHFFFAOYSA-N 2-[2-oxo-2-[4-(trifluoromethyl)phenyl]ethylidene]-5,5-bis(pyridin-4-ylmethyl)-3-[(4,6,6-trimethyl-3-bicyclo[3.1.1]heptanyl)methyl]imidazolidin-4-one Chemical compound CC1C(C2(C)C)CC2CC1CN(C1=O)C(=CC(=O)C=2C=CC(=CC=2)C(F)(F)F)NC1(CC=1C=CN=CC=1)CC1=CC=NC=C1 CQPLXXQRHANTEN-UHFFFAOYSA-N 0.000 description 1
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
GETMKVRSDFVVHL-UHFFFAOYSA-N 2-methyl-n-[3-(trifluoromethyl)phenyl]propanamide Chemical compound CC(C)C(=O)NC1=CC=CC(C(F)(F)F)=C1 GETMKVRSDFVVHL-UHFFFAOYSA-N 0.000 description 1
XQZDASCBSIMCDH-UHFFFAOYSA-N 3-(1-adamantyl)-2-phenacylidene-5,5-bis(pyridin-4-ylmethyl)imidazolidin-4-one Chemical compound C=1C=CC=CC=1C(=O)C=C(N(C1=O)C23CC4CC(CC(C4)C2)C3)NC1(CC=1C=CN=CC=1)CC1=CC=NC=C1 XQZDASCBSIMCDH-UHFFFAOYSA-N 0.000 description 1
QBVFUHQMKXCQIA-UHFFFAOYSA-N 3-[2-[5-oxo-4,4-bis(pyridin-4-ylmethyl)-1-[(4,6,6-trimethyl-3-bicyclo[3.1.1]heptanyl)methyl]imidazolidin-2-ylidene]acetyl]benzonitrile Chemical compound CC1C(C2(C)C)CC2CC1CN(C1=O)C(=CC(=O)C=2C=C(C=CC=2)C#N)NC1(CC=1C=CN=CC=1)CC1=CC=NC=C1 QBVFUHQMKXCQIA-UHFFFAOYSA-N 0.000 description 1
XQGDEPVNJFKZOC-UHFFFAOYSA-N 3-cyclohexyl-2-phenacylidene-5,5-bis(pyridin-4-ylmethyl)imidazolidin-4-one Chemical compound C=1C=CC=CC=1C(=O)C=C(N(C1=O)C2CCCCC2)NC1(CC=1C=CN=CC=1)CC1=CC=NC=C1 XQGDEPVNJFKZOC-UHFFFAOYSA-N 0.000 description 1
BNGGQUMNZUHKFH-UHFFFAOYSA-N 3-hexyl-2-phenacylidene-5,5-bis(pyridin-4-ylmethyl)imidazolidin-4-one Chemical compound O=C1N(CCCCCC)C(=CC(=O)C=2C=CC=CC=2)NC1(CC=1C=CN=CC=1)CC1=CC=NC=C1 BNGGQUMNZUHKFH-UHFFFAOYSA-N 0.000 description 1
125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 description 1
BVSDUBGRKQRZEG-UHFFFAOYSA-N 3-tert-butyl-2-phenacylidene-5,5-bis(pyridin-4-ylmethyl)imidazolidin-4-one Chemical compound O=C1N(C(C)(C)C)C(=CC(=O)C=2C=CC=CC=2)NC1(CC=1C=CN=CC=1)CC1=CC=NC=C1 BVSDUBGRKQRZEG-UHFFFAOYSA-N 0.000 description 1
ZDRFJUHLOUAEMB-UHFFFAOYSA-N 4-[2-[1-(2,2-diethoxyethyl)-5-oxo-4,4-bis(pyridin-4-ylmethyl)imidazolidin-2-ylidene]acetyl]benzonitrile Chemical compound O=C1N(CC(OCC)OCC)C(=CC(=O)C=2C=CC(=CC=2)C#N)NC1(CC=1C=CN=CC=1)CC1=CC=NC=C1 ZDRFJUHLOUAEMB-UHFFFAOYSA-N 0.000 description 1
KRUNPYRZQAFLEJ-UHFFFAOYSA-N 4-[2-[1-(2,2-dimethylpropyl)-5-oxo-4,4-bis(pyridin-4-ylmethyl)imidazolidin-2-ylidene]acetyl]benzonitrile Chemical compound O=C1N(CC(C)(C)C)C(=CC(=O)C=2C=CC(=CC=2)C#N)NC1(CC=1C=CN=CC=1)CC1=CC=NC=C1 KRUNPYRZQAFLEJ-UHFFFAOYSA-N 0.000 description 1
BAUCEUABZQQACW-UHFFFAOYSA-N 4-[2-[1-(2-adamantylmethyl)-5-oxo-4,4-bis(pyridin-4-ylmethyl)imidazolidin-2-ylidene]acetyl]benzonitrile Chemical compound C=1C=C(C#N)C=CC=1C(=O)C=C(N(C1=O)CC2C3CC4CC(C3)CC2C4)NC1(CC=1C=CN=CC=1)CC1=CC=NC=C1 BAUCEUABZQQACW-UHFFFAOYSA-N 0.000 description 1
SNHXOLWFTFMQRX-UHFFFAOYSA-N 4-[2-[1-(4-tert-butylphenyl)-5-oxo-4,4-bis(pyridin-4-ylmethyl)imidazolidin-2-ylidene]acetyl]benzonitrile Chemical compound C1=CC(C(C)(C)C)=CC=C1N1C(=O)C(CC=2C=CN=CC=2)(CC=2C=CN=CC=2)NC1=CC(=O)C1=CC=C(C#N)C=C1 SNHXOLWFTFMQRX-UHFFFAOYSA-N 0.000 description 1
HTIGSRSLFCCWJL-UHFFFAOYSA-N 4-[2-[1-(cyclohexylmethyl)-5-oxo-4,4-bis(pyridin-4-ylmethyl)imidazolidin-2-ylidene]acetyl]benzonitrile Chemical compound C=1C=C(C#N)C=CC=1C(=O)C=C(N(C1=O)CC2CCCCC2)NC1(CC=1C=CN=CC=1)CC1=CC=NC=C1 HTIGSRSLFCCWJL-UHFFFAOYSA-N 0.000 description 1
ASOHTCZUNLYTEE-UHFFFAOYSA-N 4-[2-[1-[(4-ethyl-6,6-dimethyl-3-bicyclo[3.1.1]heptanyl)methyl]-5-oxo-4,4-bis(pyridin-4-ylmethyl)imidazolidin-2-ylidene]acetyl]benzonitrile Chemical compound CCC1C(C2(C)C)CC2CC1CN(C1=O)C(=CC(=O)C=2C=CC(=CC=2)C#N)NC1(CC=1C=CN=CC=1)CC1=CC=NC=C1 ASOHTCZUNLYTEE-UHFFFAOYSA-N 0.000 description 1
XBUIEEBGCPDBMR-UHFFFAOYSA-N 4-[2-[1-[(6,6-dimethyl-4-methylidene-3-bicyclo[3.1.1]heptanyl)methyl]-5-oxo-4,4-bis(pyridin-4-ylmethyl)imidazolidin-2-ylidene]acetyl]benzonitrile Chemical compound CC1(C)C(C2)CC1C(=C)C2CN(C1=O)C(=CC(=O)C=2C=CC(=CC=2)C#N)NC1(CC=1C=CN=CC=1)CC1=CC=NC=C1 XBUIEEBGCPDBMR-UHFFFAOYSA-N 0.000 description 1
PMVYZGASWGYUFP-UHFFFAOYSA-N 4-[2-[1-[(6,6-dimethyl-4-oxo-3-bicyclo[3.1.1]heptanyl)methyl]-5-oxo-4,4-bis(pyridin-4-ylmethyl)imidazolidin-2-ylidene]acetyl]benzonitrile Chemical compound CC1(C)C(C2)CC1C(=O)C2CN(C1=O)C(=CC(=O)C=2C=CC(=CC=2)C#N)NC1(CC=1C=CN=CC=1)CC1=CC=NC=C1 PMVYZGASWGYUFP-UHFFFAOYSA-N 0.000 description 1
NOVIDQDQWGUOGE-UHFFFAOYSA-N 4-[2-[1-[(6,6-dimethyl-4-prop-1-en-2-yl-3-bicyclo[3.1.1]heptanyl)methyl]-5-oxo-4,4-bis(pyridin-4-ylmethyl)imidazolidin-2-ylidene]acetyl]benzonitrile Chemical compound CC(=C)C1C(C2(C)C)CC2CC1CN(C1=O)C(=CC(=O)C=2C=CC(=CC=2)C#N)NC1(CC=1C=CN=CC=1)CC1=CC=NC=C1 NOVIDQDQWGUOGE-UHFFFAOYSA-N 0.000 description 1
ILRHODGSSPJQLC-UHFFFAOYSA-N 4-[2-[1-[(6,6-dimethyl-4-propan-2-yl-3-bicyclo[3.1.1]heptanyl)methyl]-5-oxo-4,4-bis(pyridin-4-ylmethyl)imidazolidin-2-ylidene]acetyl]benzonitrile Chemical compound CC(C)C1C(C2(C)C)CC2CC1CN(C1=O)C(=CC(=O)C=2C=CC(=CC=2)C#N)NC1(CC=1C=CN=CC=1)CC1=CC=NC=C1 ILRHODGSSPJQLC-UHFFFAOYSA-N 0.000 description 1
PDNZMBLSTMHPFP-UHFFFAOYSA-N 4-[2-[1-[[4-hydroxy-4-(hydroxymethyl)-6,6-dimethyl-3-bicyclo[3.1.1]heptanyl]methyl]-5-oxo-4,4-bis(pyridin-4-ylmethyl)imidazolidin-2-ylidene]acetyl]benzonitrile Chemical compound CC1(C)C(C2)CC1C(O)(CO)C2CN(C1=O)C(=CC(=O)C=2C=CC(=CC=2)C#N)NC1(CC=1C=CN=CC=1)CC1=CC=NC=C1 PDNZMBLSTMHPFP-UHFFFAOYSA-N 0.000 description 1
LOGAFIMQMIOXIW-UHFFFAOYSA-N 4-[2-[5-oxo-1-phenyl-4,4-bis(pyridin-4-ylmethyl)imidazolidin-2-ylidene]acetyl]benzonitrile Chemical compound C=1C=C(C#N)C=CC=1C(=O)C=C(N(C1=O)C=2C=CC=CC=2)NC1(CC=1C=CN=CC=1)CC1=CC=NC=C1 LOGAFIMQMIOXIW-UHFFFAOYSA-N 0.000 description 1
125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 description 1
125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
206010000830 Acute leukaemia Diseases 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
206010061424 Anal cancer Diseases 0.000 description 1
208000007860 Anus Neoplasms Diseases 0.000 description 1
108010039627 Aprotinin Proteins 0.000 description 1
102000015790 Asparaginase Human genes 0.000 description 1
108010024976 Asparaginase Proteins 0.000 description 1
206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
239000005711 Benzoic acid Substances 0.000 description 1
206010005003 Bladder cancer Diseases 0.000 description 1
108010006654 Bleomycin Proteins 0.000 description 1
206010005949 Bone cancer Diseases 0.000 description 1
208000018084 Bone neoplasm Diseases 0.000 description 1
206010006143 Brain stem glioma Diseases 0.000 description 1
TYJVOGMEBGZRRD-UHFFFAOYSA-N C1(=CC=CC2=CC=CC=C12)N1C(NC(C1=O)(CC1=CC=NC=C1)CC1=CC=NC=C1)=CC(C1=CC=CC=C1)=O Chemical compound C1(=CC=CC2=CC=CC=C12)N1C(NC(C1=O)(CC1=CC=NC=C1)CC1=CC=NC=C1)=CC(C1=CC=CC=C1)=O TYJVOGMEBGZRRD-UHFFFAOYSA-N 0.000 description 1
KFGQEGXOOFPMSZ-UHFFFAOYSA-N CON=C(C)C1C(C2(C)C)CC2CC1CN(C1=O)C(=CC(=O)C=2C=CC(=CC=2)C#N)NC1(CC=1C=CN=CC=1)CC1=CC=NC=C1 Chemical compound CON=C(C)C1C(C2(C)C)CC2CC1CN(C1=O)C(=CC(=O)C=2C=CC(=CC=2)C#N)NC1(CC=1C=CN=CC=1)CC1=CC=NC=C1 KFGQEGXOOFPMSZ-UHFFFAOYSA-N 0.000 description 1
239000004215 Carbon black (E152) Substances 0.000 description 1
229920001268 Cholestyramine Polymers 0.000 description 1
208000001333 Colorectal Neoplasms Diseases 0.000 description 1
CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
102100022874 Dexamethasone-induced Ras-related protein 1 Human genes 0.000 description 1
235000019739 Dicalciumphosphate Nutrition 0.000 description 1
208000001976 Endocrine Gland Neoplasms Diseases 0.000 description 1
206010014733 Endometrial cancer Diseases 0.000 description 1
206010014759 Endometrial neoplasm Diseases 0.000 description 1
208000000461 Esophageal Neoplasms Diseases 0.000 description 1
201000001342 Fallopian tube cancer Diseases 0.000 description 1
208000013452 Fallopian tube neoplasm Diseases 0.000 description 1
229940124226 Farnesyltransferase inhibitor Drugs 0.000 description 1
GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
HEMJJKBWTPKOJG-UHFFFAOYSA-N Gemfibrozil Chemical compound CC1=CC=C(C)C(OCCCC(C)(C)C(O)=O)=C1 HEMJJKBWTPKOJG-UHFFFAOYSA-N 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
239000007995 HEPES buffer Substances 0.000 description 1
101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 1
239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
208000017604 Hodgkin disease Diseases 0.000 description 1
208000010747 Hodgkins lymphoma Diseases 0.000 description 1
101000620808 Homo sapiens Dexamethasone-induced Ras-related protein 1 Proteins 0.000 description 1
208000035150 Hypercholesterolemia Diseases 0.000 description 1
102000014150 Interferons Human genes 0.000 description 1
108010050904 Interferons Proteins 0.000 description 1
206010061252 Intraocular melanoma Diseases 0.000 description 1
208000008839 Kidney Neoplasms Diseases 0.000 description 1
240000007472 Leucaena leucocephala Species 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
208000032271 Malignant tumor of penis Diseases 0.000 description 1
240000003183 Manihot esculenta Species 0.000 description 1
235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
241001590997 Moolgarda engeli Species 0.000 description 1
208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
LKJPYSCBVHEWIU-UHFFFAOYSA-N N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide Chemical compound C=1C=C(C#N)C(C(F)(F)F)=CC=1NC(=O)C(O)(C)CS(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-UHFFFAOYSA-N 0.000 description 1
PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
206010030155 Oesophageal carcinoma Diseases 0.000 description 1
206010033128 Ovarian cancer Diseases 0.000 description 1
206010061535 Ovarian neoplasm Diseases 0.000 description 1
102000004316 Oxidoreductases Human genes 0.000 description 1
108090000854 Oxidoreductases Proteins 0.000 description 1
208000000821 Parathyroid Neoplasms Diseases 0.000 description 1
208000002471 Penile Neoplasms Diseases 0.000 description 1
206010034299 Penile cancer Diseases 0.000 description 1
102000003992 Peroxidases Human genes 0.000 description 1
ZJPGOXWRFNKIQL-JYJNAYRXSA-N Phe-Pro-Pro Chemical compound C([C@H](N)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(O)=O)C1=CC=CC=C1 ZJPGOXWRFNKIQL-JYJNAYRXSA-N 0.000 description 1
206010060862 Prostate cancer Diseases 0.000 description 1
208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
208000000236 Prostatic Neoplasms Diseases 0.000 description 1
201000004681 Psoriasis Diseases 0.000 description 1
208000015634 Rectal Neoplasms Diseases 0.000 description 1
229940123934 Reductase inhibitor Drugs 0.000 description 1
206010038389 Renal cancer Diseases 0.000 description 1
208000006265 Renal cell carcinoma Diseases 0.000 description 1
229940124639 Selective inhibitor Drugs 0.000 description 1
244000000231 Sesamum indicum Species 0.000 description 1
235000003434 Sesamum indicum Nutrition 0.000 description 1
208000000453 Skin Neoplasms Diseases 0.000 description 1
208000021712 Soft tissue sarcoma Diseases 0.000 description 1
244000061456 Solanum tuberosum Species 0.000 description 1
235000002595 Solanum tuberosum Nutrition 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
229930182558 Sterol Natural products 0.000 description 1
208000005718 Stomach Neoplasms Diseases 0.000 description 1
108090000992 Transferases Proteins 0.000 description 1
102000004357 Transferases Human genes 0.000 description 1
102000004338 Transferrin Human genes 0.000 description 1
208000023915 Ureteral Neoplasms Diseases 0.000 description 1
206010046392 Ureteric cancer Diseases 0.000 description 1
208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
201000005969 Uveal melanoma Diseases 0.000 description 1
201000003761 Vaginal carcinoma Diseases 0.000 description 1
JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
206010047741 Vulval cancer Diseases 0.000 description 1
240000008042 Zea mays Species 0.000 description 1
235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 description 1
235000002017 Zea mays subsp mays Nutrition 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
201000005188 adrenal gland cancer Diseases 0.000 description 1
208000024447 adrenal gland neoplasm Diseases 0.000 description 1
229940009456 adriamycin Drugs 0.000 description 1
230000002411 adverse Effects 0.000 description 1
239000008272 agar Substances 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
125000003282 alkyl amino group Chemical group 0.000 description 1
125000005037 alkyl phenyl group Chemical group 0.000 description 1
239000002168 alkylating agent Substances 0.000 description 1
229940100198 alkylating agent Drugs 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000002280 anti-androgenic effect Effects 0.000 description 1
229940046836 anti-estrogen Drugs 0.000 description 1
230000001833 anti-estrogenic effect Effects 0.000 description 1
230000003388 anti-hormonal effect Effects 0.000 description 1
230000001028 anti-proliverative effect Effects 0.000 description 1
239000000051 antiandrogen Substances 0.000 description 1
229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
201000011165 anus cancer Diseases 0.000 description 1
229960004405 aprotinin Drugs 0.000 description 1
239000013011 aqueous formulation Substances 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
150000008209 arabinosides Chemical class 0.000 description 1
229960003272 asparaginase Drugs 0.000 description 1
DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 1
238000003556 assay Methods 0.000 description 1
VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
229960001561 bleomycin Drugs 0.000 description 1
OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
210000005013 brain tissue Anatomy 0.000 description 1
239000000872 buffer Substances 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
229960003563 calcium carbonate Drugs 0.000 description 1
235000010216 calcium carbonate Nutrition 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
239000002775 capsule Substances 0.000 description 1
229960004562 carboplatin Drugs 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
239000000969 carrier Substances 0.000 description 1
229940097647 casodex Drugs 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
208000025997 central nervous system neoplasm Diseases 0.000 description 1
208000019065 cervical carcinoma Diseases 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
235000012000 cholesterol Nutrition 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
229960004316 cisplatin Drugs 0.000 description 1
229960001214 clofibrate Drugs 0.000 description 1
KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 description 1
208000029742 colonic neoplasm Diseases 0.000 description 1
239000003086 colorant Substances 0.000 description 1
238000003271 compound fluorescence assay Methods 0.000 description 1
235000009508 confectionery Nutrition 0.000 description 1
238000011254 conventional chemotherapy Methods 0.000 description 1
210000004748 cultured cell Anatomy 0.000 description 1
208000030381 cutaneous melanoma Diseases 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
229960004397 cyclophosphamide Drugs 0.000 description 1
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
229960003964 deoxycholic acid Drugs 0.000 description 1
NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
229940038472 dicalcium phosphate Drugs 0.000 description 1
229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
239000000975 dye Substances 0.000 description 1
238000001378 electrochemiluminescence detection Methods 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
201000004101 esophageal cancer Diseases 0.000 description 1
239000000328 estrogen antagonist Substances 0.000 description 1
CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical compound CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
229960005420 etoposide Drugs 0.000 description 1
238000004299 exfoliation Methods 0.000 description 1
208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
208000028149 female reproductive system neoplasm Diseases 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
229960002949 fluorouracil Drugs 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
238000009472 formulation Methods 0.000 description 1
206010017758 gastric cancer Diseases 0.000 description 1
239000000499 gel Substances 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
229960003627 gemfibrozil Drugs 0.000 description 1
229960002989 glutamic acid Drugs 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
229960002449 glycine Drugs 0.000 description 1
201000010536 head and neck cancer Diseases 0.000 description 1
235000009200 high fat diet Nutrition 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
239000000367 immunologic factor Substances 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
229940079322 interferon Drugs 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
201000010982 kidney cancer Diseases 0.000 description 1
239000008101 lactose Substances 0.000 description 1
108010052968 leupeptin Proteins 0.000 description 1
GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
239000012139 lysis buffer Substances 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
235000009973 maize Nutrition 0.000 description 1
230000036210 malignancy Effects 0.000 description 1
208000029559 malignant endocrine neoplasm Diseases 0.000 description 1
208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
208000026037 malignant tumor of neck Diseases 0.000 description 1
208000026045 malignant tumor of parathyroid gland Diseases 0.000 description 1
229960001961 meglutol Drugs 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
230000000394 mitotic effect Effects 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
229960003512 nicotinic acid Drugs 0.000 description 1
235000001968 nicotinic acid Nutrition 0.000 description 1
239000011664 nicotinic acid Substances 0.000 description 1
229940085033 nolvadex Drugs 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
201000002575 ocular melanoma Diseases 0.000 description 1
239000008203 oral pharmaceutical composition Substances 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
208000011932 ovarian sarcoma Diseases 0.000 description 1
230000002018 overexpression Effects 0.000 description 1
125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
108010054353 p21(ras) farnesyl-protein transferase Proteins 0.000 description 1
230000000849 parathyroid Effects 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
108040007629 peroxidase activity proteins Proteins 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
229940127557 pharmaceutical product Drugs 0.000 description 1
239000006187 pill Substances 0.000 description 1
229930006728 pinane Natural products 0.000 description 1
208000010916 pituitary tumor Diseases 0.000 description 1
229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
239000002243 precursor Substances 0.000 description 1
230000002265 prevention Effects 0.000 description 1
208000016800 primary central nervous system lymphoma Diseases 0.000 description 1
239000000047 product Substances 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
235000004252 protein component Nutrition 0.000 description 1
239000003528 protein farnesyltransferase inhibitor Substances 0.000 description 1
238000010814 radioimmunoprecipitation assay Methods 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
230000035484 reaction time Effects 0.000 description 1
206010038038 rectal cancer Diseases 0.000 description 1
201000001275 rectum cancer Diseases 0.000 description 1
230000008844 regulatory mechanism Effects 0.000 description 1
230000004044 response Effects 0.000 description 1
208000037803 restenosis Diseases 0.000 description 1
238000000926 separation method Methods 0.000 description 1
230000019491 signal transduction Effects 0.000 description 1
150000004760 silicates Chemical class 0.000 description 1
201000000849 skin cancer Diseases 0.000 description 1
201000003708 skin melanoma Diseases 0.000 description 1
201000002314 small intestine cancer Diseases 0.000 description 1
239000011734 sodium Substances 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
229960001790 sodium citrate Drugs 0.000 description 1
235000011083 sodium citrates Nutrition 0.000 description 1
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 description 1
239000008247 solid mixture Substances 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
150000003432 sterols Chemical class 0.000 description 1
235000003702 sterols Nutrition 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
201000011549 stomach cancer Diseases 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
239000000758 substrate Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000006188 syrup Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
229960001603 tamoxifen Drugs 0.000 description 1
201000002510 thyroid cancer Diseases 0.000 description 1
210000001685 thyroid gland Anatomy 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
229940044693 topoisomerase inhibitor Drugs 0.000 description 1
238000012546 transfer Methods 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
229910052722 tritium Inorganic materials 0.000 description 1
210000003708 urethra Anatomy 0.000 description 1
201000005112 urinary bladder cancer Diseases 0.000 description 1
229960003048 vinblastine Drugs 0.000 description 1
JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
201000004916 vulva carcinoma Diseases 0.000 description 1
208000013013 vulvar carcinoma Diseases 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
238000005303 weighing Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Hematology (AREA)
Oncology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Plural Heterocyclic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

BG103946A 1997-06-16 1999-12-03 Инхибитори на фарнезилтрансфераза в комбинация с инхибитори на нмg соа редуктаза за лечение на рак BG103946A (bg)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US4963897P	1997-06-16	1997-06-16
PCT/IB1998/000881 WO1998057633A1 (en)	1997-06-16	1998-06-05	FARNESYL TRANSFERASE INHIBITORS IN COMBINATION WITH HMG CoA REDUCTASE INHIBITORS FOR THE TREATMENT OF CANCER

Publications (1)

Publication Number	Publication Date
BG103946A true BG103946A (bg)	2000-07-31

Family

ID=21960890

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BG103946A BG103946A (bg)	1997-06-16	1999-12-03	Инхибитори на фарнезилтрансфераза в комбинация с инхибитори на нмg соа редуктаза за лечение на рак

Country Status (37)

Country	Link
EP (1)	EP0986387B1 (no)
JP (1)	JP3713051B2 (no)
KR (1)	KR100392573B1 (no)
CN (1)	CN1259868A (no)
AP (1)	AP9801261A0 (no)
AR (1)	AR013090A1 (no)
AT (1)	ATE235905T1 (no)
BG (1)	BG103946A (no)
BR (1)	BR9810616A (no)
CA (1)	CA2294399C (no)
CO (1)	CO4950607A1 (no)
DE (1)	DE69812933T2 (no)
DK (1)	DK0986387T3 (no)
DZ (1)	DZ2518A1 (no)
EA (1)	EA199901043A1 (no)
ES (1)	ES2196559T3 (no)
GT (1)	GT199800081A (no)
HN (1)	HN1998000091A (no)
HR (1)	HRP980328B1 (no)
HU (1)	HUP0004624A3 (no)
ID (1)	ID23014A (no)
IL (1)	IL132765A0 (no)
IS (1)	IS5259A (no)
MA (1)	MA24569A1 (no)
NO (1)	NO996206L (no)
NZ (1)	NZ500662A (no)
OA (1)	OA11231A (no)
PA (1)	PA8453601A1 (no)
PE (1)	PE82899A1 (no)
PL (1)	PL337651A1 (no)
PT (1)	PT986387E (no)
SK (1)	SK169699A3 (no)
TN (1)	TNSN98088A1 (no)
TR (1)	TR199903074T2 (no)
UA (1)	UA57081C2 (no)
WO (1)	WO1998057633A1 (no)
ZA (1)	ZA985182B (no)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1999058505A2 (en) *	1998-05-12	1999-11-18	Warner-Lambert Company	Combinations of protein farnesyltransferase and hmg coa reductase inhibitors and their use to treat cancer
WO2000016778A1 (en) *	1998-09-24	2000-03-30	Merck & Co., Inc.	A method of treating cancer
EP1006113A1 (en)	1998-12-02	2000-06-07	Pfizer Products Inc.	Derivatives of 2-(2-oxo-ethylidene)-imidazolidin-4-one and their use to inhibit abnormal cell growth
AU4988100A (en) *	1999-05-07	2000-11-21	Brigham And Women's Hospital	Use of hmgcoa reductase inhibitors in the prevention of diseases whose pathogenesis is dependent on neovascularization
US6710058B2 (en)	2000-11-06	2004-03-23	Bristol-Myers Squibb Pharma Company	Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors
EP1395577A1 (en)	2000-12-19	2004-03-10	Pfizer Products Inc.	Crystal forms of 6- (4-chloro-phenyl)-hydroxy-(-3-methyl-3h-imidaol-4-yl)-methyl]-4-(3-ethynyl-phenyl)-1-methyl-1h-quinolin-2-one, 2,3-dihydroxybutanedioate salts and method of production
DE60122939T2 (de)	2000-12-21	2007-01-11	Nitromed, Inc., Bedford	Substituierte arylverbindungen als neue, cyclooxygenase-2-selektive inhibitoren, zusammensetzungen und verwendungsverfahren
US20020151563A1 (en) *	2001-03-29	2002-10-17	Pfizer Inc.	Farnesyl transferase inhibitors in combination with HMG CoA reductase inhibitors for the inhibition of abnormal cell growth
US6740757B2 (en)	2001-08-29	2004-05-25	Pfizer Inc	Enantiomers of 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3h-imidazol-4-yl)-methyl]-4-[3-(3-hydroxy-3-methyl-but-1-ynyl)-phenyl]-1-methyl-1h-quinolin-2-one and salts thereof, useful in the treatment of cancer
TWI297606B (en) *	2004-01-16	2008-06-11	Nat Health Research Institutes	Cancer therapy
US8168667B2 (en)	2006-05-31	2012-05-01	Galapagos Nv	Imidazolidine derivatives, uses therefor, preparation thereof and compositions comprising such
GB2463514C (en)	2008-09-11	2018-09-26	Galapagos Nv	Imidazolidine compounds and uses therefor

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0856315B1 (en) *	1995-08-09	2005-08-24	Banyu Pharmaceutical Co., Ltd.	Protein-farnesyltransferase inhibitors in combination with hmgcoa-reductase-inhibitors for the treatment of aids

1998
- 1998-05-06 UA UA99126842A patent/UA57081C2/uk unknown
- 1998-06-05 NZ NZ500662A patent/NZ500662A/en unknown
- 1998-06-05 PT PT98921688T patent/PT986387E/pt unknown
- 1998-06-05 TR TR1999/03074T patent/TR199903074T2/xx unknown
- 1998-06-05 EP EP98921688A patent/EP0986387B1/en not_active Expired - Lifetime
- 1998-06-05 KR KR10-1999-7011860A patent/KR100392573B1/ko not_active IP Right Cessation
- 1998-06-05 HU HU0004624A patent/HUP0004624A3/hu unknown
- 1998-06-05 CN CN98805968A patent/CN1259868A/zh active Pending
- 1998-06-05 JP JP50403099A patent/JP3713051B2/ja not_active Expired - Fee Related
- 1998-06-05 BR BR9810616-3A patent/BR9810616A/pt not_active Application Discontinuation
- 1998-06-05 WO PCT/IB1998/000881 patent/WO1998057633A1/en not_active Application Discontinuation
- 1998-06-05 EA EA199901043A patent/EA199901043A1/ru unknown
- 1998-06-05 CA CA002294399A patent/CA2294399C/en not_active Expired - Fee Related
- 1998-06-05 IL IL13276598A patent/IL132765A0/xx unknown
- 1998-06-05 SK SK1696-99A patent/SK169699A3/sk unknown
- 1998-06-05 DK DK98921688T patent/DK0986387T3/da active
- 1998-06-05 AT AT98921688T patent/ATE235905T1/de not_active IP Right Cessation
- 1998-06-05 ES ES98921688T patent/ES2196559T3/es not_active Expired - Lifetime
- 1998-06-05 DE DE69812933T patent/DE69812933T2/de not_active Expired - Fee Related
- 1998-06-05 ID IDW991597A patent/ID23014A/id unknown
- 1998-06-05 PL PL98337651A patent/PL337651A1/xx unknown
- 1998-06-09 HN HN1998000091A patent/HN1998000091A/es unknown
- 1998-06-11 AP APAP/P/1998/001261A patent/AP9801261A0/en unknown
- 1998-06-12 PE PE1998000500A patent/PE82899A1/es not_active Application Discontinuation
- 1998-06-12 AR ARP980102812A patent/AR013090A1/es unknown
- 1998-06-15 GT GT199800081A patent/GT199800081A/es unknown
- 1998-06-15 TN TNTNSN98088A patent/TNSN98088A1/fr unknown
- 1998-06-15 DZ DZ980128A patent/DZ2518A1/xx active
- 1998-06-15 PA PA19988453601A patent/PA8453601A1/es unknown
- 1998-06-15 MA MA25114A patent/MA24569A1/fr unknown
- 1998-06-15 ZA ZA9805182A patent/ZA985182B/xx unknown
- 1998-06-16 HR HR980328A patent/HRP980328B1/xx not_active IP Right Cessation
- 1998-06-16 CO CO98034148A patent/CO4950607A1/es unknown
1999
- 1999-11-19 IS IS5259A patent/IS5259A/is unknown
- 1999-12-03 BG BG103946A patent/BG103946A/bg unknown
- 1999-12-10 OA OA9900276A patent/OA11231A/en unknown
- 1999-12-15 NO NO996206A patent/NO996206L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
KR100392573B1 (ko)	2003-07-23
ES2196559T3 (es)	2003-12-16
AP9801261A0 (en)	1999-12-11
JP3713051B2 (ja)	2005-11-02
IS5259A (is)	1999-11-19
OA11231A (en)	2003-05-26
SK169699A3 (en)	2000-06-12
PT986387E (pt)	2003-06-30
CA2294399A1 (en)	1998-12-23
EP0986387A1 (en)	2000-03-22
NO996206D0 (no)	1999-12-15
MA24569A1 (fr)	1998-12-31
DZ2518A1 (fr)	2003-02-01
NZ500662A (en)	2001-10-26
DK0986387T3 (da)	2003-07-14
JP2000513031A (ja)	2000-10-03
EA199901043A1 (ru)	2000-06-26
CA2294399C (en)	2004-03-16
DE69812933T2 (de)	2003-11-06
ZA985182B (en)	1999-12-17
NO996206L (no)	2000-02-15
PA8453601A1 (es)	2000-05-24
AR013090A1 (es)	2000-12-13
ID23014A (id)	1999-12-30
PL337651A1 (en)	2000-08-28
HRP980328A2 (en)	1999-04-30
GT199800081A (es)	1999-12-07
PE82899A1 (es)	1999-08-26
UA57081C2 (uk)	2003-06-16
HN1998000091A (es)	1999-09-29
IL132765A0 (en)	2001-03-19
AU7445998A (en)	1999-01-04
KR20010013839A (ko)	2001-02-26
WO1998057633A1 (en)	1998-12-23
HRP980328B1 (en)	2002-06-30
AU724676B2 (en)	2000-09-28
BR9810616A (pt)	2000-09-12
ATE235905T1 (de)	2003-04-15
HUP0004624A3 (en)	2002-11-28
HUP0004624A2 (hu)	2001-10-28
EP0986387B1 (en)	2003-04-02
TNSN98088A1 (fr)	2005-03-15
DE69812933D1 (de)	2003-05-08
CO4950607A1 (es)	2000-09-01
CN1259868A (zh)	2000-07-12
TR199903074T2 (xx)	2000-05-22

Publication	Publication Date	Title
JP6473330B2 (ja)	2019-02-20	ＲａｌＧＴＰアーゼを標的とする抗がん化合物及びその使用方法
JP4130179B2 (ja)	2008-08-06	骨髄腫を処置するためのｃ−ｋｉｔ阻害剤の使用
JP2010523682A (ja)	2010-07-15	癌及び他の疾患の治療に有用なカルボリン誘導体の投与
BG103946A (bg)	2000-07-31	Инхибитори на фарнезилтрансфераза в комбинация с инхибитори на нмg соа редуктаза за лечение на рак
KR20010032304A (ko)	2001-04-16	알도스 환원효소 억제제 및 글리코겐 포스포릴라제억제제의 혼합물
ES2896735T3 (es)	2022-02-25	Eflornitina para su uso en el tratamiento del astrocitoma anaplásico recurrente/refractario por temozolomida
IL305317A (en)	2023-10-01	Preparations and methods for regulating hair growth
JP6864379B2 (ja)	2021-04-28	インドール類似体及びその使用
JP2000510828A (ja)	2000-08-22	腫瘍崩壊剤および放射線療法の臨床効果を増強するためのプロテインキナーゼｃ阻害剤の使用
JP2004525942A (ja)	2004-08-26	化合物および方法
EA001779B1 (ru)	2001-08-27	Способ лечения заболеваний, связанных с фактором роста сосудистого эндотелия
US20040077661A1 (en)	2004-04-22	Treatment of tuberous sclerosis associated neoplasms
AU2002211862B2 (en)	2007-03-15	Methods of inducing cancer cell death and tumor regression
CN107207510A (zh)	2017-09-26	联合疗法
WO2024124000A1 (en)	2024-06-13	Treatment of myeloproliferative diseases and disorders with inhibitors of bet family bdii bromodomain
AU724676C (en)	2001-05-03	Farnesyl transferase inhibitors in combination with hmg CoA reductase inhibitors for the treatment of cancer
US20030114503A1 (en)	2003-06-19	Farnesyl transferase inhibitors in combination with HMG CoA reductase inhibitors for the treatment of cancer
CZ448699A3 (cs)	2000-04-12	Inhibitory farnesyltransferasy v kombinaci s inhibitory HMG CoA reduktasy pro léčení rakoviny
KR20000035861A (ko)	2000-06-26	Ａｉｄｓ 치료용 약제를 제조하기 위한 ｐｋｃ 억제제의 사용 방법
MXPA99011798A (en)	2000-06-01	FARNESYL TRANSFERASE INHIBITORS IN COMBINATION WITH HMG CoA REDUCTASE INHIBITORS FOR THE TREATMENT OF CANCER
WO2002078706A1 (en)	2002-10-10	Farnesyl transferase inhibitors in combination with hmg coa reductase inhibitors for the inhibition for the treatment of cancer
WO2021086912A1 (en)	2021-05-06	Combined pikfyve and p38 map kinase inhibition for treating cancer
EP3503888A1 (en)	2019-07-03	Inhibitors of-bcr-abl mutants and use thereof
JP4227121B2 (ja)	2009-02-18	神経因性疼痛治療剤
EA042675B1 (ru)	2023-03-13	Лиганд рецептора гамк-а